JW gains solid tumor technology license through recent acquisition
By Nikita Chaurasia  Date: 2020-07-21

JW gains solid tumor technology license through recent acquisition

JW Therapeutics, a biotechnology company headquartered in Shanghai, China, has reportedly acquired Syracuse Biopharma (Hong Kong) Ltd., inclusive of a licensing agreement for Eureka Therapeutics’ solid tumor technology and ARTEMIS® antibody TCR for exclusive use in China and ASEAN nations.

Earlier this month, JW Therapeutics collaborated with Acepodia for the commercialization of two of company’s cell therapy candidates for treating solid tumors and hematologic malignancies.

Dr. James Li, Co-Founder and Head of JW Therapeutics, stated that the company is excited to declare the acquisition of Syracuse for strengthening its clinical expertise in solid tumor cancers. Syracuse and Eureka have devised a unique and effective approach for treating solid tumors with their T-cell receptor antibody mimic antibody (TCRm-Ab) and ARTEMIS® technologies. The company is looking to forward to work with them to deliver the next generation of T cell immunotherapies to patients, he added.

On the other side, Founder and CEO of Eureka Therapeutics, Dr. Cheng Liu is equally excited to work with JW Therapeutics for having recognized the value of the propriety ARTEMIS® platform. With the help of JW, the company is looking to leverage the new-found resources to speed up the development of T cell therapies for its battle against solid tumors.

The number of hepatocellular carcinoma (HCC) cases in China is very high and JW is strategically positioned to develop these therapies and increase its accessibility to patients across China, he added.

Founder and President of Eureka Therapeutics, Dr. Cheng Liu, will now be a part of the Board of Directors at JW Therapeutics, while the Chief Business Officer and General Counsel of Eureka, Victor Shum, will take on the role of a Board Observer, claim credible sources.

The terms of the deal have not been disclosed so far.

Sources: https://www.businesswire.com/news/home/20200720005179/en/JW-Therapeutics-Acquires-Syracuse-Biopharma-License-Eureka

https://www.globenewswire.com/news-release/2020/07/14/2061786/0/en/Acepodia-and-JW-Therapeutics-Enter-into-Option-and-License-Agreement-for-Off-the-shelf-NK-Cell-Therapies.html

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Helix Technologies, MOR Analytics to unite under new banner Forian Inc.
Helix Technologies, MOR Analytics to unite under new banner Forian Inc.
By Nikita Chaurasia

According to reliable sources, U.S.-based critical infrastructure service provider of cannabis industry, Helix Technologies Inc. has reportedly announced a strategic merger with Medical Outcomes Research Analytics LLC (MOR Analytics) to become wholly...

German software firm Celonis launches the market’s first EMS
German software firm Celonis launches the market’s first EMS
By Nikita Chaurasia

Celonis, a German leader in AI-enhanced Process Excellence and Process Mining, has reportedly launched the first EMS (Execution Management System) of the industry. The company has specifically developed the EMS to remove system complexity, which is t...

Informatica adds advanced capabilities to enterprise cloud platform
Informatica adds advanced capabilities to enterprise cloud platform
By Nikita Chaurasia

Informatica, a leading US based enterprise cloud data management firm, has reportedly rolled out new, enhanced capabilities that are designed to help its clients become cloud-native, cloud-first in the COVID-19 pandemic. IDC (International Data Corpo...

Nokia bags Chunghwa Telecom’s small-cell deal for 5G expansion
Nokia bags Chunghwa Telecom’s small-cell deal for 5G expansion
By Nikita Chaurasia

Finnish multinational communications company Nokia Corp. has reportedly entered into a supply agreement with Taiwan-based mobile operator Chunghwa Telecom (CHT). As per the agreement, Nokia will provide CHT with a wide range of products from their in...

Varian’s IDE win makes way for first ever FLASH therapy clinical trial
Varian’s IDE win makes way for first ever FLASH therapy clinical trial
By Nikita Chaurasia

U.S.-based radiotherapy technology company, Varian Medical Systems has made it to the headlines for reportedly receiving an IDE (Investigational Device Exemption) from the U.S. Food & Drug Administration. For the uninitiated, FLASH therapy is an...